For type 2 diabetes mellitus. ANDA 207427, held by Regcon Holdings. Metformin Hydrochloride.
As of Nov 16, 2026, ANDA 207427 (Metformin Hydrochloride), held by Regcon Holdings, was first approved by FDA on Dec 13, 2016, with 2 approved supplements and 0 published complete response letters.
Metformin hydrochloride extended-release tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 13, 2016 | Original application | Approved | None posted |
| Metformin Hydrochloride500MG · tablet, extended release;oral | Metformin Hydrochloride | Rx |
| Metformin Hydrochloride750MG · tablet, extended release;oral | Metformin Hydrochloride | Rx |
| Aug 11, 2026 | Supplement 16Labeling · Standard review | Approved | None posted |
| Jul 27, 2026 | Supplement 10Labeling · Standard review | Approved | None posted |
| Dec 13, 2016 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters